Search ENDV
ENDONOVO THERAPEUTICS, INC.
OTC · CIK 1528172
Last close0
Daily changen/a
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ENDV · STANDARD
SIC 3845 · Electromedical & Electrotherapeutic Apparatus · Fiscal year end 1231
Fundamental
42.2Momentum
100.0Acceleration
100.0Confidence
82.0Annual Revenue11
Quarterly Revenue33
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.7 / 25
Quality21.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet7.8 / 15
Shareholder Economics3.1 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 5.3675 percentage points.
Operating leverageOperating margin improved by 6838.3496 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 905.356%.
Key Metrics
Revenue Growth TTM254.14%OK
Revenue CAGR 3Y-24.15%OK
Gross Margin93.91%OK
Operating Margin-1,811.17%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO-13.41xOK
Diluted Share Growth 1Y905.36%OK
SBC / Revenue4.13%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2022 FY Dec 31, 2022 | $135,355.00 | $125,365.00 | -$3.26M | -$678,838.00 | n/a | 92.62% | -2,411.69% | n/a | n/a | n/a |
| 2022 FY Dec 31, 2021 | $73,105.00 | $58,120.00 | -$2.23M | -$986,584.00 | n/a | 79.5% | -3,045.68% | n/a | n/a | n/a |
| 2021 FY Dec 31, 2020 | $165,796.00 | $100,427.00 | -$2.91M | -$741,590.00 | n/a | 60.57% | -1,756.49% | n/a | n/a | n/a |
| 2020 FY Dec 31, 2019 | $310,164.00 | $216,779.00 | -$3.81M | -$2.54M | -$2.54M | 69.89% | -1,228.08% | -820.08% | n/a | n/a |
| 2019 FY Dec 31, 2018 | $83,263.00 | $70,333.00 | -$4.16M | -$2.88M | -$2.89M | 84.47% | -4,995.33% | -3,468.29% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $145,220.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-23-046561, 0001493152-23-018538 |
| Revenue Growth TTM | 254.14% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-23-046561, 0001493152-23-018538 |
| Revenue CAGR 3Y | -24.15% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-23-012553 |
| Revenue CAGR 5Y | 99.67% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-23-012553 |
| Gross Profit CAGR 3Y | -16.69% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-23-012553 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-23-046561, 0001493152-23-018538 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 93.91% | Gross Profit / Revenue | OK | 0001493152-23-046561, 0001493152-23-018538 |
| Operating Margin | -1,811.17% | Operating Income / Revenue | OK | 0001493152-23-046561, 0001493152-23-018538 |
| Net Debt / CFO | -13.41x | Net Debt / CFO | OK | 0001493152-23-046561, 0001493152-23-029706 |
| Current Ratio | 0x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0x | (Cash + Short-term Investments) / Total Debt | OK | 0001493152-23-046561 |
| SBC / Revenue | 4.13% | SBC / Revenue | OK | 0001493152-23-046561, 0001493152-23-029706 |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001493152-23-046561, 0001493152-23-018538 |